Vanessa
Roldan Schilling
Catedraticos de Universidad Vinculados H.V.Arrixaca
![Foto de Vanessa](/img/uploaded/aab593d7615a80d42da1c23d7d2bc16b.jpeg)
![Foto de University of Liverpool](/img/noimage_org.png)
University of Liverpool
Liverpool, Reino UnidoPublicaciones en colaboración con investigadores/as de University of Liverpool (13)
2023
-
Imaging in atrial fibrillation: A way to assess atrial fibrosis and remodeling to assist decision-making
American Heart Journal, Vol. 258, pp. 1-16
-
Impact of particulate matter on the incidence of atrial fibrillation and the risk of adverse clinical outcomes: A review
Science of the Total Environment, Vol. 880
-
Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?
Biomedicine and Pharmacotherapy, Vol. 158
2022
-
Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper
Thrombosis and Haemostasis, Vol. 122, Núm. 10, pp. 1625-1652
-
Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 24, Núm. 11, pp. 1844-1871
-
Editorial: New horizons in the management of patients with atrial fibrillation: Interactions with the gastrointestinal system
Frontiers in Cardiovascular Medicine
-
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry
European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46
2021
-
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
Europace, Vol. 23, Núm. 10, pp. 1612-1676
-
Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics
Frontiers in Cardiovascular Medicine
2020
-
Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-bleeding scores in patients with atrial fibrillation: The Murcia AF project
Thrombosis and Haemostasis, Vol. 120, Núm. 8, pp. 1200-1207
-
Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy
Expert Opinion on Pharmacotherapy, pp. 1867-1881
2019
-
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals
Clinical Pharmacology and Therapeutics, Vol. 105, Núm. 6, pp. 1477-1491
-
The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal
Thrombosis and Haemostasis, Vol. 119, Núm. 12, pp. 1901-1919